# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new ...
Jefferies analyst Tycho Peterson assumes Myriad Genetics (NASDAQ:MYGN) with a Underperform rating and lowers Price Target of...
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiat...
Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from ...
Leerink Partners analyst Puneet Souda upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and raises th...